Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIRPα antisense morpholino
- Development stage
- Preclinical
- Lead developer
- Wake Forest University School of Medicine
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
SIRPα antisense morpholino is a synthetic antisense oligonucleotide designed to knockdown the expression of Signal Regulatory Protein Alpha (SIRPα). While SIRPα is traditionally known for its role on myeloid cells where it binds CD47 to inhibit phagocytosis, research indicates it is also expressed on malignant cells in glioblastoma (GBM). This morpholino-mediated blockade inhibits mitochondrial fatty acid β-oxidation (FAO) in GBM cells, leading to decreased mitochondrial ATP production. Furthermore, targeting SIRPα on GBM cells enhances microglia-mediated cytotoxicity, suggesting that SIRPα regulates both tumor metabolism and immune evasion in the brain tumor microenvironment.
- Other names
- SIRPα morpholinoSIRPα antisense oligonucleotide
02
Targets
SIRPA (Signal-regulatory protein alpha)
Beyond the preview
Go deeper on SIRPα antisense morpholino.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIRPα antisense morpholino.